Table 1.
Placebo | Acetaminophen | |
---|---|---|
Performance | ||
Peak MVC (N m) | 221 ± 49 | 230 ± 38 |
Mean torque (% MVC) | 58 ± 14 | 61 ± 11* |
Total torque-impulse (N m s) | 22,055 ± 3885 | 24,386 ± 3792* |
CT (% MVC) | 40 ± 15 | 44 ± 12* |
Wʹ (N m s) | 6971 ± 2432 | 6906 ± 2537 |
Neuromuscular function | ||
End-exercise pTw (N m) | 30 ± 20 | 31 ± 23 |
End-exercise contraction time (ms) | 83.2 ± 10.9 | 81.3 ± 14.0 |
End-exercise half-relaxation time (ms) | 72.5 ± 17.2 | 75.5 ± 17.5 |
End-exercise MRFD (N m s) | 1330 ± 471 | 1230 ± 433 |
End-exercise VA (%) | 59 ± 19 | 62 ± 16 |
End-exercise M-wave amplitude (%) | 96 ± 14 | 95 ± 18 |
End-exercise M-wave amplitude (mV) | 5.64 ± 2.59 | 5.44 ± 2.72 |
End-exercise EMG amplitude (%) | 59 ± 17 | 87 ± 28* |
MVC maximal voluntary contraction, CT critical torque measured in the last six contractions; mean torque measured as average torque across the 60 MVC test, pTw potentiated twitch force, MRFD maximal rate of force development, VA voluntary activation measured using the interpolated twitch method technique, EMG electromyography, N m newton metres, N m s newton metres per second, ms milliseconds
*Significantly different from placebo (P < 0.05)